Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients
Abstract Aim To investigate the impact of biological subtypes in locoregional recurrence in Chinese breast cancer patients receiving postmastectomy radiotherapy (PMRT). Methods and Materials About 583 patients who received postmastectomy radiation between 2010 and 2012 were retrospectively analyzed....
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2904 |
| _version_ | 1819063510701703168 |
|---|---|
| author | Jiangfeng Wang Jurui Luo Kairui Jin Xuanyi Wang Zhaozhi Yang Jinli Ma Xin Mei Xiaofang Wang Zhirui Zhou Xiaoli Yu Xingxing Chen Xiaomao Guo |
| author_facet | Jiangfeng Wang Jurui Luo Kairui Jin Xuanyi Wang Zhaozhi Yang Jinli Ma Xin Mei Xiaofang Wang Zhirui Zhou Xiaoli Yu Xingxing Chen Xiaomao Guo |
| author_sort | Jiangfeng Wang |
| collection | DOAJ |
| description | Abstract Aim To investigate the impact of biological subtypes in locoregional recurrence in Chinese breast cancer patients receiving postmastectomy radiotherapy (PMRT). Methods and Materials About 583 patients who received postmastectomy radiation between 2010 and 2012 were retrospectively analyzed. According to immunohistochemical staining profile, patients were classified into: Luminal A‐like, Luminal B‐like, HER2‐positive, and triple‐negative breast cancer (TNBC). Local and regional recurrence (LRR) cumulative incidences were calculated by competing risks methodology and the power of prognostic factors was examined by Gray's test and the test of Fine and Gray. Results The median follow‐up was 70.9 months. About 34 LRR events occurred. For Luminal A, Luminal B, HER2‐positive, and TNBC patients, the 5‐year LRR cumulative incidence rates were 1.57%, 4.09%, 10.74%, and 10.28%. Compared with Luminal A, HER2‐positive subtype and TNBC had a significant increased risk of LRR (HR was 5.034 and 5.188, respectively). In univariate analysis, predictive factors for higher LRR were HER2‐positive subtype (HR = 4.43, P < .05), TNBC (HR = 4.70, P < .05), and pN3 (HR = 5.83, P < .05). In the multivariate model, HER2‐positive subtype (HR = 5.034, P < .05), TNBC (HR = 5.188, P < .05), and pN3 (HR = 9.607, P < .01) were independent predictors of LRR. LRR without trastuzumab was similar to that of TNBC (without vs TNBC, 17.88% vs 10.28%, P > .05) in HER2‐positive subtype patients, while LRR with trastuzumab was approximate to Luminal A (with vs Luminal A, P > .05). Additionally, endocrine therapy also significantly reduced LRR incidence in the luminal subtype cohort (without vs with therapy, 6.25% vs 2.89%, HR = 0.365, P < .1). Conclusions Biological subtype was a prognostic factor of LRR in the PMRT setting among Chinese breast cancer patients. |
| first_indexed | 2024-12-21T15:15:50Z |
| format | Article |
| id | doaj.art-b6d9ba77e0934a7087f896d275314cf6 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-21T15:15:50Z |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-b6d9ba77e0934a7087f896d275314cf62022-12-21T18:59:10ZengWileyCancer Medicine2045-76342020-04-01972427243410.1002/cam4.2904Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patientsJiangfeng Wang0Jurui Luo1Kairui Jin2Xuanyi Wang3Zhaozhi Yang4Jinli Ma5Xin Mei6Xiaofang Wang7Zhirui Zhou8Xiaoli Yu9Xingxing Chen10Xiaomao Guo11Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai ChinaAbstract Aim To investigate the impact of biological subtypes in locoregional recurrence in Chinese breast cancer patients receiving postmastectomy radiotherapy (PMRT). Methods and Materials About 583 patients who received postmastectomy radiation between 2010 and 2012 were retrospectively analyzed. According to immunohistochemical staining profile, patients were classified into: Luminal A‐like, Luminal B‐like, HER2‐positive, and triple‐negative breast cancer (TNBC). Local and regional recurrence (LRR) cumulative incidences were calculated by competing risks methodology and the power of prognostic factors was examined by Gray's test and the test of Fine and Gray. Results The median follow‐up was 70.9 months. About 34 LRR events occurred. For Luminal A, Luminal B, HER2‐positive, and TNBC patients, the 5‐year LRR cumulative incidence rates were 1.57%, 4.09%, 10.74%, and 10.28%. Compared with Luminal A, HER2‐positive subtype and TNBC had a significant increased risk of LRR (HR was 5.034 and 5.188, respectively). In univariate analysis, predictive factors for higher LRR were HER2‐positive subtype (HR = 4.43, P < .05), TNBC (HR = 4.70, P < .05), and pN3 (HR = 5.83, P < .05). In the multivariate model, HER2‐positive subtype (HR = 5.034, P < .05), TNBC (HR = 5.188, P < .05), and pN3 (HR = 9.607, P < .01) were independent predictors of LRR. LRR without trastuzumab was similar to that of TNBC (without vs TNBC, 17.88% vs 10.28%, P > .05) in HER2‐positive subtype patients, while LRR with trastuzumab was approximate to Luminal A (with vs Luminal A, P > .05). Additionally, endocrine therapy also significantly reduced LRR incidence in the luminal subtype cohort (without vs with therapy, 6.25% vs 2.89%, HR = 0.365, P < .1). Conclusions Biological subtype was a prognostic factor of LRR in the PMRT setting among Chinese breast cancer patients.https://doi.org/10.1002/cam4.2904biological subtypebreast cancerradiotherapyrecurrence |
| spellingShingle | Jiangfeng Wang Jurui Luo Kairui Jin Xuanyi Wang Zhaozhi Yang Jinli Ma Xin Mei Xiaofang Wang Zhirui Zhou Xiaoli Yu Xingxing Chen Xiaomao Guo Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients Cancer Medicine biological subtype breast cancer radiotherapy recurrence |
| title | Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients |
| title_full | Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients |
| title_fullStr | Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients |
| title_full_unstemmed | Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients |
| title_short | Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients |
| title_sort | biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in chinese breast cancer patients |
| topic | biological subtype breast cancer radiotherapy recurrence |
| url | https://doi.org/10.1002/cam4.2904 |
| work_keys_str_mv | AT jiangfengwang biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT juruiluo biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT kairuijin biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT xuanyiwang biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT zhaozhiyang biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT jinlima biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT xinmei biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT xiaofangwang biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT zhiruizhou biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT xiaoliyu biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT xingxingchen biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients AT xiaomaoguo biologicalsubtypepredictslocoregionalrecurrenceafterpostmastectomyradiotherapyinchinesebreastcancerpatients |